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Abstract
Background: Thymosin a1( T a1), a 28-amino acid N
a-acetylated peptide, has a powerful general
immunostimulating activity. Although biosynthesis is an attractive means of large-scale manufacture, to date, Ta1
can only be chemosynthesized because of two obstacles to its biosynthesis: the difficulties in expressing small
peptides and obtaining N
a-acetylation. In this study, we describe a novel production process for N
a-acetylated Ta1
in Escherichia coli.
Results: To obtain recombinant N
a-acetylated Ta1 efficiently, a fusion protein, Ta1-Intein, was constructed, in
which Ta1 was fused to the N-terminus of the smallest mini-intein, Spl DnaX (136 amino acids long, from Spirulina
platensis), and a His tag was added at the C-terminus. Because Ta1 was placed at the N-terminus of the Ta1-Intein
fusion protein, Ta1 could be fully acetylated when the Ta1-Intein fusion protein was co-expressed with RimJ (a
known prokaryotic N
a-acetyltransferase) in Escherichia coli. After purification by Ni-Sepharose affinity
chromatography, the Ta1-Intein fusion protein was induced by the thiols b-mercaptoethanol or d,l-dithiothreitol, or
by increasing the temperature, to release Ta1 through intein-mediated N-terminal cleavage. Under the optimal
conditions, more than 90% of the Ta1-Intein fusion protein was thiolyzed, and 24.5 mg Ta1 was obtained from 1 L
of culture media. The purity was 98% after a series of chromatographic purification steps. The molecular weight of
recombinant Ta1 was determined to be 3107.44 Da by mass spectrometry, which was nearly identical to that of
the synthetic version (3107.42 Da). The whole sequence of recombinant Ta1 was identified by tandem mass
spectrometry and its N-terminal serine residue was shown to be acetylated.
Conclusions: The present data demonstrate that N
a-acetylated Ta1 can be efficiently produced in recombinant E.
coli. This bioprocess could be used as an alternative to chemosynthesis for the production of Ta1. The described
methodologies may also be helpful for the biosynthesis of similar peptides.
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Background
The increasing use of peptides as pharmaceutical agents,
especially in the antiviral and anti-infective therapeutic
areas, requires cost-effective production on a large scale
[1]. Thymosin a1( T a1), with its primary structure Ac-
SDAAVDTSSEITTKDLKEK KEVVEEAEN, has a power-
ful general immunostimulating activity. Ta1 is a promis-
ing medicine and is currently used for the treatment of
various bacterial infections (including antibiotic-resistant
tuberculosis), viral diseases (hepatitis B and C), and as
an anti-tumor agent [2].
Currently, Ta1 is either isolated from calf thymus
using a multistage chromatographic purification or is
obtained by chemical synthesis [3,4]. The chemosyn-
thetic version of Ta1 has now been launched by
SciClone under the trade name Zadaxin in approxi-
mately forty countries for the treatment of hepatitis B.
Primary research indicates that Zadaxin may be also
useful in treating a number of other diseases, including
hepatitis C, non-small cell lung cancer, melanoma, and
HIV/AIDS. In addition, Zadaxin is also indicated as a
vaccine adjuvant, to enhance the effectiveness of the
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production cost, a biotechnological approach using
recombinant gene expression in bacteria seems promis-
ing. However, there are two main obstacles to the bio-
synthesis of Ta1: the bacterial expression of small
peptides is difficult in general; and this protein requires
N-terminal acetylation.
It is well known that direct expression of small poly-
peptides in E. coli is unsuccessful in most cases, because
short peptides are often subject to degradation by pro-
teases in the host cells, which leads to a significant
decrease in yield and confers difficulties in separating
the target peptides from their degraded fragments [6].
Several approaches have been taken to improve the
expression of small peptides and to alleviate proteolysis,
one of which is to fuse the target peptide to a carrier
protein named the “fusion partner” [7,8]. The fusion
partner is often highly expressed in the host cells with
an affinity tag. This not only elevates the expression
level of the fusion protein and thus the yield of the tar-
get peptide, but also facilitates purification of the fusion
protein. One problem of this approach is the use of che-
mical reagents or proteases to cleave the target peptide
from its fusion partner. While the use of proteases may
be expensive and sometimes non-specific, chemical
methods usually require harsh reaction conditions that
may damage or structurally modify the target peptides,
in addition to having a low specificity and reducing
yield.
Fortunately, several of these problems can be solved
by using intein-mediated protein purification. The
intein-mediated self-cleavage system has been recently
developed as a powerful tool for protein expression,
purification, ligation, and amidation [9-14]. Target pep-
tides can be synthesized with fusions that have been
genetically engineered to achieve cleavage of the peptide
bond at either the N- or C-terminus without the use of
specific proteases or chemical reagents [9-12,14,15].
Thymosins have been successfully expressed in E. coli in
this way [16,17]. However, the yield is still low and an
in vitro acetylation step is required. Recently, an in vitro
non-enzymatic acetylation of recombinant Ta1w a s
reported [18]. However, because in all previous cases
thymosins have been fused to the C-terminus of the
fusion partner, they cannot be acetylated at the N-termi-
nus in vivo.
In a previous study, we revealed that N-terminal acet-
ylation of recombinant Ta1-fused protein in E. coli is
catalyzed by RimJ, and that fully acetylated Ta1 can be
obtained by co-expressing it with RimJ [19]. This was
the first description that acetylation of an ectopic pro-
tein in E. coli could be catalyzed by RimJ, a well-known
prokaryotic N-terminal acetyltransferase. To produce
Ta1, we constructed a fusion protein, named Ta1-
Intein, in which Ta1 was fused to the N-terminus of a
mini-intein, Spl DnaX intein (136 amino acids) [20].
The Spl DnaX intein identified in the cyanobacterium
Spirulina platensis is the smallest thus far identified,
although its splicing activity has not been experimentally
proven [21]. For N-terminal cleavage, we constructed a
modified Spl DnaX intein with a C-terminal alanine
residue instead of asparagine [22]. Here, we show that
this small, modified mini-intein is very suitable for N-
terminal cleavage to release Ta1.
Materials and methods
Bacterial strains, media, and reagents
E. coli DH5a (F
-, supE44, ΔlacU169 (80, lacZΔM15),
hsdR17, recA1, endA1, gyrA96, thi, relA1) was used for
all plasmid propagation and its genome was used as a
template for amplifying rimJ. E. coli BL21(DE3) (F
-,
ompT, hsdSB(rB
-mB
-), gal, dcm, (DE3)) was used for
expressing proteins. Plasmids pET22b(+), pET28a(+),
and pACYCDuet-1 (Novagen, EMD Chemicals, Darm-
stadt, Germany) were used as expression vectors. All the
restriction enzymes, T4 DNA ligase, Pyrobest™ DNA
polymerase, and DNA molecular weight marker were
from TaKaRa Biotechnology (Dalian, China). Protein
low molecular weight marker was purchased from GE
Healthcare. Synthetic Ta1 was from SciClone Pharma-
ceuticals International Ltd. (Hong Kong, China). Other
chemicals used in this study were of analytical or higher
grade. The primers were synthesized by Shanghai San-
gon Biological Engineering Technology & Services (San-
gon; Shanghai, China).
Plasmid construction
Construction of plasmid pACYC-rimJ for the expression
of RimJ has been described elsewhere [19]. The gene
that encodes the Spl DnaX intein (136 amino acid resi-
dues; from Spirulina platensis) was designed with the E.
coli codon bias to ensure high expression in E. coli.I t
contains EcoRI and XhoI restriction enzyme sites. We
mutated the C-terminal amino acid from Asn to Ala. To
introduce an AflII site, we also mutated the third amino
acid at the N-terminus from Thr to Ser. The gene was
synthesized by Sangon. The gene product and vector
pET22b(+) were both digested with EcoRI and XhoI.
The fragments were purified after 1% agarose gel elec-
trophoresis, and then ligated using T4 DNA ligase to
yield plasmid pET-S.
Two partially complementary, single-stranded DNA
oligonucleotides encoding the entire human Ta1b u t
with E. coli codon preference were synthesized. The
sequences were forward primer, TA (5;-GAA TTC CAT
ATG TCA GAT GCA GCA GTA GAT ACT AGC TCT
GAA ATC ACT ACC AAA GAC CTG AAG GAG
AAG AAG-3;) containing an NdeI site (underlined), and
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GTT CTC AGC CTC TTC GAC AAC TTC CTT CTT
CTC CTT CAG GTC-3;) containing an AflII site
(underlined). The conditions for PCR amplification were
as follows: 95°C for 5 min; 30 cycles of 94°C for 30 s,
56°C for 30 s, and 72°C for 10 s, with a final hold for an
extra 10 min at 72°C. The PCR product and vector
pET-S were both digested with NdeI and AflII. The
fragments were purified by 1% agarose gel electrophor-
esis, then ligated using T4 DNA ligase to generate
expression plasmid pET-Ta1-Intein. Clones were
selected by ampicillin screening, and then the positive
clones were checked by DNA sequencing to ensure they
contained the correct Ta1-Intein sequence.
Protein expression and purification of the Ta1-Intein
fusion protein and optimization of cleavage conditions
E. coli strain BL21 (DE3) was transformed with the plas-
mids pACYC-rimJ and pET-Ta1-Intein to express Ta1-
Intein and RimJ. The strain was cultivated in the auto-
inducible medium FML (K2HPO4￿3H2O, 7 g/L; NaH2-
PO4￿2H2O, 3 g/L; NaCl, 2.5 g/L; yeast extract, 12 g/L;
tryptone, 15 g/L; MgSO4￿7H2O ,0 . 5g / L ;g l u c o s e ,2g / L ;
lactose, 0.722 g/L), containing 100 μg/ml ampicillin and
50 μg/ml chloramphenicol at 37°C, with shaking at 230
rpm for 12 h. Cells were harvested by centrifugation
(5,000 × g, 20 min, 4°C); 10.5 g of wet cells were
obtained from 1 L of culture fluid. For Ta1-Intein puri-
fication, the cell pellets were resuspended in buffer A
(50 mM sodium phosphate, 0.5 M NaCl, 20 mM imida-
zole, pH 7.0) and lysed by sonication for 30 min (4 s
working, 5 s free) in an ice-water bath. Soluble protein
was separated from cell debris by centrifugation at
15,000 × g,4 ° Cf o r3 0m i n ,f i l t e r e dt h r o u g ha0 . 4 5 - μm
membrane, and loaded onto a 20 ml HisTrap Fast Flow
column (GE Healthcare, Fairfield, CT, USA) pre-equili-
brated with buffer A, using Ni-Sepharose affinity chro-
matography. Bound proteins were eluted with buffer B
(50 mM sodium phosphate, 0.5 M NaCl, 400 mM imi-
dazole, pH 7.0), and then the peak fractions, including
Ta1-Intein, were pooled and stored at -20°C.
The purified fusion protein Ta1-Intein was incubated
with 100 mM b-mercaptoethanol (b-ME) or d,l-dithio-
threitol (DTT) at different temperatures (4, 30, 37, 42,
55, or 60°C) for 24 h. As a control, purified Ta1-Intein
was incubated at the same temperature for 24 h in the
absence of b-ME and DTT. All reactions were termi-
nated by mixing the protein samples with 2× sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE) buffer and boiling for 3 min. The proteins were
separated by 17% SDS-PAGE followed by staining with
Coomassie Brilliant Blue. The stained gels were digitized
with an HP4400C (Hewlett-Packard, Palo Alto, CA,
USA) and the scanned images were analyzed with Gel-
Pro software (Media Cybernetics, Inc., Bethesda, MD,
USA). The percentage of cleavage was determined by
the intensity of the precursor Ta1-Intein band of the
sample compared with that of the control.
Purification and characterization of recombinant Ta1
The solution of Ta1-Intein fusion protein was supple-
mented with 100 mM b- M Ea n di n c u b a t e da t4 2 ° Cf o r
24 h. Before centrifugation, ammonium sulfate was
added to the eluate to approximately 1 M. The superna-
tant was adjusted to pH 7.0 and filtered through a 0.45-
μm membrane, then loaded onto a Phenyl Sepharose 6
Fast Flow column (high sub) (GE Healthcare) that had
been pre-equilibrated with buffer C (50 mM sodium
phosphate with 1 M ammonium sulfate, pH 7.0).
According to previous experiments, the Ta1 target pro-
tein was in the through fractions. To acquire highly
pure Ta1, we pooled the through fractions and then
applied them to a SORCE30 RPC column (GE Health-
care) that had been pre-equilibrated with buffer D (0.1%
H3PO4), eluted fractions on a gradient of 100 ml, 0-
100% buffer E (25% v/v acetonitrile, 0.1% H3PO4), and
collected the elution fractions containing the target pro-
tein. After adjusting the pH to 7.0, the eluate was finally
loaded onto a Q Sepharose Fast Flow column pre-equili-
brated with buffer F (50 mM sodium phosphate, pH 7.0)
followed by elution on a linear gradient of 100 ml, 0-
100% buffer G (50 mM sodium phosphate, 1 M NaCl,
pH 7.0). The elution fractions containing the target pro-
tein were pooled.
After this multi-stage chromatographic purification,
the yield and purity of recombinant Ta1w e r ea n a l y z e d
using reverse phase-high performance liquid chromato-
graphy (RP-HPLC) using a Hypersil 300 Å C18 5-μm
column, with a 14-25% acetonitrile/0.1% H3PO4 gradient
and a 1 ml/min flow rate.
The molecular mass of recombinant Ta1w a sd e t e r -
mined by quadrupole time-of-flight (Q-TOF) mass spec-
trometry (MS) using a Q-TOF 2 mass spectrometer
(Micromass, UK) after desalting the sample on a C18
Zip-Tip (Millipore, Billerica, MA) and eluting the pro-
duct in acetonitrile, water, and trifluoroacetic acid
(50:50:0.5). The whole sequence of recombinant Ta1
was identified by tandem MS.
The biological activity of Ta1 was determined by E-
rosette assay [23]. Briefly, fresh pig thymus lymphocytes
were placed with RPMI-1640 and 100 μg/L recombinant
Ta1 for 2 h at 37°C, 50 mL/L CO2 in a humidified incu-
bator, using chemosynthetic Ta1-Zadaxin (SciClone
Pharmaceuticals, Inc.) and Hank’s buffer as parallel con-
trols. Sheep red blood cells were then added and incu-
bation continued for another 3 h. The percentage of E-
rosette-forming cells (ERFC) was calculated by counting
the number of E-rosette-forming lymphocytes out of a
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three times. The biological activity was defined as the
percentage of ERFC in the sample minus the percentage
of ERFC in the Hank’s buffer control.
Results
Protein expression and purification of Ta1-Intein and
optimization the cleavage conditions
To obtain N
a-acetylated human Ta1, Ta1-Intein and
RimJ were expressed from plasmids pET-Ta1-Intein
and pACYC-rimJ, respectively, in E. coli strain BL21
(DE3). The fusion protein Ta1-Intein (19749 Da; amino
acid sequence shown in Figure 1) was purified using Ni-
Sepharose affinity chromatography on a single HisTrap
FF column, then treated at different temperatures with
or without 100 mM b-ME or DTT. As the modified
mini-intein has Ala as its C-terminal residue instead of
Asn, the Ta1-Intein fusion protein can undergo N-
terminal cleavage to release Ta1, as shown in Figure 2.
The amount of cleavage increased with increasing tem-
perature. At 55°C, approximately 80% of Ta1-Intein was
hydrolyzed after 24 h, but at 60°C, the Ta1b a n d
became weaker and the intein band did not (Figure 3A).
This may be because of hydrolysis of Ta1. In the pre-
sence of 100 mM b-ME or 100 mM DTT, the cleavage
efficiency was more than 90% at 42°C after 24 h. The
efficiency of N-terminal cleavage induced by DTT was
slightly higher than that induced by the same concentra-
tion of b-ME (Figure 3B). However, the molecular
weight of the Ta1 obtained from thiolyzed Ta1-Intein
with 100 mM DTT was not uniform. A spurious peak,
18 Da smaller than the calculated value (see peaks 1
and 2 in Figure 4) was observed. The whole sequence of
peak 1 was identified by Q-TOF MS/MS and its C-
terminal Asn residue was shown to be dehydrated (data
not shown). Considering the stability and cleavage effi-
ciency of the Ta1-Intein fusion protein, the optimal
cleavage conditions were established to be 100 mM b-
ME at 42°C for 24 h.
Purification and characterization of recombinant Ta1
Recombinant N
a-acetylated Ta1 was purified from a 1-L
shaking flask culture of bacteria as described above (Fig-
ure 5). The final amount and the purity of Ta1w e r e
24.5 mg and 98%, respectively, as determined by RP-
HPLC.
Figure 1 Amino acid sequence of the fusion protein Ta1-Intein
(thymosin a1-Spl DnaX intein).
Figure 2 N-terminal cleavage mediated by the modified mini-
intein to release Ta1.
Figure 3 Induction of cleavage at the N-terminus of the intein
in the Ta1-Intein fusion protein. A. Cleavage of purified Ta1-
Intein fusion protein was induced at various temperatures for 24 h.
“M”, molecular weight marker; “control”, pre-incubation sample. B.
The purified Ta1-Intein fusion protein was incubated at different
temperatures for 24 h. “control”, pre-incubation sample; “-”, without
b-ME or DTT; “ME”, with 100 mM b-ME; “DTT”, with 100 mM DTT.
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binant Ta1, and analyzed the mixture using RP-HPLC.
Because there was only one peak, this indicated that the
HPLC retention time of recombinant Ta1 was identical
to that of the synthetic Ta1 standard (data not shown).
The molecular weight of synthetic Ta1 (3107.42 Da;
Figure 6A) was determined by MS to be almost identical
to that of recombinant Ta1 (3107.44 Da; Figure 6B).
The Q-TOF MS spectra revealed several sodium adducts
(peaks at 3129, 3151, and 3173 Da; Figure 6A, B).
Instead of the sample molecules being ionized by the
addition of a proton, H
+, the molecules in these peaks
were ionized by the addition of one or more sodium
cations, Na
+. Moreover, there was no peak correspond-
ing to non-acetylated Ta1i nF i g u r e4 B ,s ot h eN - t e r m -
inal Ser of recombinant Ta1 was fully acetylated; this
was confirmed by Q-TOF MS/MS (data not shown).
These results suggest that intein-mediated protein
Figure 4 Q-TOF-MS analysis of recombinant Ta1 released from the Ta1-Intein fusion protein by DTT-induced cleavage. “peak 1”,t h e
dehydrated form of recombinant Ta1; “peak 2”, the normal form of recombinant Ta1.
Figure 5 SDS-PAGE of Ta1 expression and purification. Lane 1: molecular weight marker; Lane 2: non-induced bacterial lysate cultured in LB
medium; Lane 3: induced bacterial lysate cultured in FML medium; Lane 4: Ta1-Intein purified by Ni-Sepharose; Lane 5: Ta1-Intein incubated
with 100 mM b-mercaptoethanol (ME) at 42°C for 24 h; Lane 6: combined through fractions, after Phenyl Sepharose 6 Fast Flow column; Lane 7:
combined eluted fractions, after SORCE30 RPC column; Lane 8: combined eluted fractions, after Q Sepharose Fast Flow column.
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that recombinant Ta1w a sN
a-acetylated on its native
primary amino acid sequence.
The percentage of ERFC was calculated by counting the
number of E-rosette-forming lymphocytes out of a total of
200 lymphocytes [23]. Recombinant Ta1 and chemosyn-
thetic Ta1 demonstrated a similar ability to increase the
percentage of ERFC (16.1 ± 3.3% (n = 3)) relative to the
number formed in the Hank’s buffer control.
Discussion
Although the requirement for Ta1 for clinical applica-
tions is increasing, Ta1 is still mainly obtained by che-
mical synthesis. While chemically synthesized Ta1 can
reach a high level of purity, it is necessary to eliminate
side products at each step, including those with incor-
rect joining and dextral compounds. Moreover, the
longer the peptide, the more intricate the chemical
synthesis process becomes. Ta1 comprises 28 amino
acids, and its chemical synthesis is expensive. Therefore,
ab i o s y n t h e t i cm e t h o du s i n gr e c o m b i n a n tg e n ee x p r e s -
sion in bacteria is desirable. Here, we expressed fully
N
a-acetylated Ta1i nE. coli using an intein fusion and
co-expression with RimJ. We thus overcame the two
common problems of E. coli polypeptide expression: the
difficulties in expressing small peptides and obtaining
N
a-acetylation.
Self-splicing intein can be mutated at the N- or C-
terminal splice junction to yield self-cleaving inteins,
which can then be used as self-cleaving purification tags.
These modified inteins can be split into two categories:
C-terminal fusion-mediated cleavage can be induced by
thiol reagents and pH, whereas N-terminal fusion-
mediated cleavage can only be thiol-induced [10]. The
expression of intein-fused thymosins has been previously
reported [16,17]; however, these C-terminal cleavage
methods suffer from a low yield and a lack of in vivo
acetylation. For efficient expression of the small peptide
Figure 6 Q-TOF MS analysis of the synthetic Ta1 standard (A) and recombinant Ta1 (B). Apart from the peak at 3107 Da, there are peaks
representing several sodium adducts at 3129, 3151, and 3173 Da.
Figure 7 Succinimide residue formation at the C-terminus of Ta1 during thiolysis.
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consisting of 136 amino acids, as the fusion partner. As
an N
a-acetylated peptide, Ta1 must be located at the
N-terminus of the fusion protein (Figure 1). Therefore,
we modified the C-terminal residue of the mini-intein
from Asn to Ala. In vivo N
a-acetylation at the N-term-
inal Ser of Ta1 was achieved by co-expression with
RimJ [19].
This modified mini-intein-mediated N-terminal clea-
vage reaction was induced by the addition of thiol
reagents and/or increasing the temperature; both fac-
tors worked cooperatively. Approximately 80% of Ta1-
Intein was hydrolyzed at 55°C after 24 h, but in the
presence of 100 mM b-ME or DTT, the extent of N-
terminal cleavage was more than 90% at 42°C after 24
h. Because the target peptide Ta1i sv e r ys t a b l ee v e n
at 80°C [4], the cleavage conditions are compatible
with the product. Although DTT induction was slightly
more efficient than b-ME induction, a proportion of
the released Ta1 was dehydrated (peak 1 in Figure 4)
at the C-terminal Asn (data not shown), a phenom-
enon that has not been previously reported. One possi-
ble mechanism for this is the formation of a
succinimide residue followed by nucleophilic attack of
the side-chain N atom of the Asn residue during thio-
lysis (Figure 7). The thioester bond of Asn with DTT
may more easily induce succinimide formation than
that with b-ME.
The small size of the Spl DnaX mini-intein (136
amino acids) and its high level of expression in E. coli
made it an attractive choice for these experiments. How-
ever, in vivo self-cleavage still reduced the yield of the
target peptide Ta1. A new methodology involving dele-
tion of the glutathione synthetase gene (gshA) has been
reported to overcome this limitation [24]. However, in
this study, deletion of gshA did not have a significant
effect on the in vivo self-cleavage of the Ta1-Intein
fusion protein (data not shown). Even with this limita-
t i o n ,w ew e r ea b l et oo b t a i n2 4 . 5m go fT a1f r o m1L
of culture media in a shaking flask, and the purity was
more than 98% after a series of chromatographic purifi-
cation steps. Furthermore, the biological activity of the
recombinant Ta1 (16.1 ± 3.3%) exceeded the 10% mini-
m u mf o rau s a b l ep r o d u c ta sd e f i n e db yt h eC h i n e s e
Pharmacopoeia; recombinant Ta1i sd e e m e dt ob e
active in enhancing the formation of T-cell receptors in
sheep erythrocytes.
Conclusions
In this study, we described an efficient procedure for the
production of large quantities of recombinant N
a-acety-
lated Ta1i nE. coli by combining N-terminal cleavage
technology mediated by fusion with the smallest mini-
intein, Spl DnaX, and co-expression with RimJ. The
method is simple and cost-effective, and presents an
attractive alternative to chemosynthetic approaches. The
methodologies described here may also be helpful in the
biosynthesis of similar peptides.
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